Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness Wire • 06/05/26
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding MembersBusiness Wire • 06/03/26
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xHBusiness Wire • 06/01/26
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug DevelopmentBusiness Wire • 05/31/26
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research CommunityBusiness Wire • 05/30/26
Tempus Introduces ‘Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive ResultsBusiness Wire • 05/30/26
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in OncologyBusiness Wire • 05/29/26
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor PortfolioBusiness Wire • 05/29/26
Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across OncologyBusiness Wire • 05/28/26
HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?Zacks Investment Research • 05/27/26
Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical WorkflowsBusiness Wire • 05/27/26
Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual MeetingBusiness Wire • 05/26/26
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical UseBusiness Wire • 05/21/26
Undercovered Dozen: Sivers Semiconductors, LandBridge, Hercules Capital, And MoreSeeking Alpha • 05/18/26
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and NeuroscienceBusiness Wire • 05/14/26
Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”Business Wire • 05/11/26
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision MedicineSeeking Alpha • 05/08/26
Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior NotesBusiness Wire • 05/08/26
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest ExpenseBusiness Wire • 05/07/26